Dr. Syed M. Kazmi
Claim this profileUT Southwestern/Simmons Cancer Center-Dallas
Studies Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
33 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
MLH1 positive
2Colon Cancer
Stage IV
Stage III
BRAF negative
Affiliated Hospitals
Clinical Trials Syed M. Kazmi is currently running
Ceralasertib + Trastuzumab Deruxtecan
for Solid Tumors
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of ceralasertib and trastuzumab deruxtecan versus trastuzumab deruxtecan alone. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Ceralasertib and trastuzumab deruxtecan may be safe, tolerable and effective in treating patients with advanced solid tumors expressing the HER2 protein or gene.
Recruiting1 award Phase 126 criteria
Repotrectinib
for Solid Tumors
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Recruiting1 award Phase 1 & 27 criteria
More about Syed M. Kazmi
Clinical Trial Related7 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Syed M. Kazmi has experience with
- Atezolizumab
- Nivolumab
- Cetuximab
- Bevacizumab
- Oxaliplatin
- Fluorouracil
Breakdown of trials Syed M. Kazmi has run
Colorectal Cancer
Colon Cancer
Rectal Cancer
Cervical Adenocarcinoma
Parotid Gland Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Syed M. Kazmi specialize in?
Is Syed M. Kazmi currently recruiting for clinical trials?
Are there any treatments that Syed M. Kazmi has studied deeply?
What is the best way to schedule an appointment with Syed M. Kazmi?
What is the office address of Syed M. Kazmi?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.